Circulating cell-free mitochondrial deoxyribonucleic acid is increased in coronary heart disease patients with diabetes mellitus.
Circulating cell-free mitochondrial deoxyribonucleic acid is increased in coronary heart disease patients with diabetes mellitus.
复制标题
冠心病合并糖尿病患者循环游离线粒体脱氧核糖核酸增加
DOI：
10.1111/jdi.12366
复制
发表时间：
2016-01
影响因子：
3.2
通讯作者：
Gong J
中科院分区：
文献类型：
--
作者：
Liu J;Zou Y;Tang Y;Xi M;Xie L;Zhang Q;Gong J
循环无细胞线粒体脱氧核糖核酸（ccf-mtDNA）可能来源于体内受损的组织或细胞，并已被认为是多种疾病的潜在生物标志物。本研究旨在探讨线粒体DNA是否可以作为冠心病（CHD）伴或不伴糖尿病（DM）患者病情评估的生物标志物。共招募了50例CHD伴2型糖尿病患者、50例CHD不伴2型糖尿病患者和50例年龄和性别匹配的CHD不伴DM（非CHD-DM）患者。通过使用定量真实的时间聚合酶链反应测量烟酰胺腺嘌呤二核苷酸脱氢酶1基因来评估Ccf‐mtDNA水平。并对冠心病合并或不合并糖尿病患者血浆mtDNA进行受试者工作特征曲线分析。多因素Logistic回归分析mtDNA水平与冠心病传统危险因素的相关性。CHD合并DM患者血浆ccf‐mtDNA水平显著高于非CHD‐ DM患者和无CHD‐DM患者。冠心病合并糖尿病患者与非冠心病合并糖尿病患者的mtDNA受试者工作特征曲线下面积为0.907%。mtDNA水平与CHD传统危险因素的相关分析显示，CHD合并DM患者mtDNA水平与空腹血糖显著相关。Ccf‐mtDNA水平可用作CHD合并DM患者的生物标志物。
Circulating cell‐free mitochondrial deoxyribonucleic acid (ccf‐mtDNA) is presumably derived from injured tissues or cells in the body and has been suggested to be potential biomarker in several diseases. The present study explored whether mtDNA could be used as a biomarker to evaluate disease in coronary heart disease (CHD) patients with or without diabetes mellitus (DM). A total of 50 CHD patients with type 2 diabetes, 50 CHD patients without type 2 diabetes, and 50 age‐ and sex‐matched patients without CHD and DM (non‐CHD‐DM) were recruited. Ccf‐mtDNA levels were assessed by measuring the nicotinamide adenine dinucleotide dehydrogenase 1 gene using quantitative real‐time polymerase chain reaction. Receiver operating characteristic curve analysis of plasma mtDNA in CHD with or without DM was also determined. Multivariate logistic regression analyses were carried out to determine the correlation between the mtDNA levels and traditional CHD risk factors. The plasma ccf‐mtDNA levels were significantly elevated in CHD patients with DM compared with those without and non‐CHD‐DM. The area under the receiver operating characteristic curves of mtDNA in CHD patients with DM vs non‐CHD‐DM was 0.907%. Correlation analyses of the mtDNA levels and traditional CHD risk factors showed that the mtDNA levels were significantly correlated with fasting blood glucose in CHD patients with DM. Ccf‐mtDNA levels can be used as a biomarker in CHD patients with DM.